Engineered immune cells take on tough lupus cases

This early-stage study is testing a new treatment called PTOC1 cells, which are a type of CAR-T cell therapy, for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target and attack lupus-causing cells. The study will enroll 18 participants to check if the treatment is safe and can reduce disease activity, with the goal of controlling the condition long-term.